Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company's product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biopharmaceuticals
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:FBIO
- CUSIP: 21976U10
- Web: www.fortressbiotech.com
Capitalization:- Market Cap: $224.85 million
- Outstanding Shares: 50,527,000
Average Prices:- 50 Day Moving Avg: $4.44
- 200 Day Moving Avg: $4.12
- 52 Week Range: $1.88 - $5.13
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.78
- P/E Growth: -0.10
Sales & Book Value:- Annual Revenue: $108.97 million
- Price / Sales: 2.09
- Book Value: $1.43 per share
- Price / Book: 3.15
Profitability:- EBIDTA: ($71,480,000.00)
- Net Margins: -53.95%
- Return on Equity: -54.88%
- Return on Assets: -30.67%
Debt:- Debt-to-Equity Ratio: 0.27%
- Current Ratio: 3.56%
- Quick Ratio: 3.55%
Misc:- Average Volume: 191,659 shs.
- Beta: 1.13
- Short Ratio: 20.13
Frequently Asked Questions for Fortress Biotech (NASDAQ:FBIO)
What is Fortress Biotech's stock symbol?
Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."
How were Fortress Biotech's earnings last quarter?
Fortress Biotech, Inc. (NASDAQ:FBIO) released its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.06. The business had revenue of $2.78 million for the quarter, compared to analyst estimates of $47.04 million. Fortress Biotech had a negative net margin of 53.95% and a negative return on equity of 54.88%. View Fortress Biotech's Earnings History.
When will Fortress Biotech make its next earnings announcement?
Where is Fortress Biotech's stock going? Where will Fortress Biotech's stock price be in 2017?
5 brokerages have issued 12-month target prices for Fortress Biotech's shares. Their forecasts range from $9.00 to $11.00. On average, they expect Fortress Biotech's share price to reach $10.60 in the next twelve months. View Analyst Ratings for Fortress Biotech.
What are analysts saying about Fortress Biotech stock?
Here are some recent quotes from research analysts about Fortress Biotech stock:
- 1. According to Zacks Investment Research, "Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States. " (9/12/2017)
- 2. FBR & Co analysts commented, "On May 10, Fortress reported 1Q17 results. The company did not host a conference call, but we had a chance to catch up with the CEO. We note that Fortress made great progress in terms of advancing its pipeline in 2017. Recent company highlights include the launch of two additional subsidiaries in the quarter, Caelum Biosciences and Cyprium Therapeutics, thereby broadening the company pipeline to include amyloid light chain (AL) amyloidosis and Menkes disease indications. We expect the company to continue to advance its pipeline and explore additional opportunities to strengthen its subsidiary company portfolio for the rest of 2017." (5/12/2017)
Who are some of Fortress Biotech's key competitors?
Some companies that are related to Fortress Biotech include Syros Pharmaceuticals (SYRS), Sinovac Biotech (SVA), ChemoCentryx (CCXI), Mirna Therapeutics (SYBX), Syndax Pharmaceuticals (SNDX), Strongbridge Biopharma PLC (SBBP), Mereo BioPharma Group PLC (MPH), Kadmon Holdings (KDMN), Kamada (KMDA), Vericel Corporation (VCEL), Peregrine Pharmaceuticals (PPHM), MediWound (MDWD), VIVUS (VVUS), Alimera Sciences (ALIM), Cardiome Pharma Corporation (CRME), Opiant Pharmaceuticals (OPNT), KalVista Pharmaceuticals (KALV) and Chiasma (CHMA).
Who are Fortress Biotech's key executives?
Fortress Biotech's management team includes the folowing people:
- Lindsay A. Rosenwald M.D., Chairman of the Board, President, Chief Executive Officer
- Eric K. Rowinsky M.D., Vice Chairman of the Board
- Robyn Hunter, Chief Financial Officer
- Michael S. Weiss, Executive Vice Chairman - Strategic Development
- Lucy Lu M.D., Executive Vice President
- George C. Avgerinos Ph.D., Senior Vice President - Biologics Operations
- Malcolm I. Hoenlein, Director
- David J. Barrett CPA,, Independent Director
- Jimmie Harvey Jr., M.D., Independent Director
- J. Jay Lobell J.D., Independent Director
Who owns Fortress Biotech stock?
Fortress Biotech's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.56%), State Street Corp (0.93%), Northern Trust Corp (0.77%), California Public Employees Retirement System (0.25%), ClariVest Asset Management LLC (0.24%) and Bank of New York Mellon Corp (0.21%). View Institutional Ownership Trends for Fortress Biotech.
Who sold Fortress Biotech stock? Who is selling Fortress Biotech stock?
Fortress Biotech's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., ClariVest Asset Management LLC, Susquehanna International Group LLP, California State Teachers Retirement System, TIAA CREF Investment Management LLC, Teachers Advisors LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Fortress Biotech.
Who bought Fortress Biotech stock? Who is buying Fortress Biotech stock?
Fortress Biotech's stock was purchased by a variety of institutional investors in the last quarter, including Abner Herrman & Brock LLC, State Street Corp, Strs Ohio, State of Wisconsin Investment Board, National Asset Management Inc., Northern Trust Corp, Parametric Portfolio Associates LLC and Rhumbline Advisers. View Insider Buying and Selling for Fortress Biotech.
How do I buy Fortress Biotech stock?
Shares of Fortress Biotech can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fortress Biotech's stock price today?
One share of Fortress Biotech stock can currently be purchased for approximately $4.51.
MarketBeat Community Rating for Fortress Biotech (NASDAQ FBIO)MarketBeat's community ratings are surveys of what our community members think about Fortress Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Fortress Biotech (NASDAQ:FBIO)Earnings History by Quarter for Fortress Biotech (NASDAQ FBIO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | ($0.43) | | | | | N/A |  |
| 5/10/2017 | Q1 2017 | ($0.36) | ($0.30) | $47.04 million | $2.78 million | View | N/A | |
| 8/9/2016 | Q2 | ($0.29) | ($0.31) | $1.07 million | $2.23 million | View | N/A | |
| 5/10/2016 | Q1 | | ($0.31) | | $0.66 million | View | N/A | |
| 3/15/2016 | Q4 | ($0.09) | ($0.31) | | $0.34 million | View | N/A | |
| 11/9/2015 | Q315 | ($0.13) | ($0.46) | | $0.03 million | View | N/A | |
| 8/10/2015 | Q2 | | ($0.16) | | | View | N/A | |
| 5/11/2015 | Q1 | | ($0.31) | | | View | N/A | |
| 3/16/2015 | Q414 | | ($0.10) | | | View | N/A | |
| 8/11/2014 | Q2 2014 | ($0.17) | ($0.13) | | | View | N/A | |
| 5/12/2014 | Q114 | ($0.18) | ($0.21) | | | View | N/A | |
| 3/14/2014 | Q413 | ($0.22) | ($0.27) | | | View | N/A | |
| 11/1/2013 | Q313 | ($0.31) | ($0.24) | | | View | N/A | |
| 8/5/2013 | Q213 | ($0.31) | ($0.38) | | | View | N/A | |
| 5/8/2013 | Q1 2013 | ($0.30) | ($0.35) | | | View | N/A | |
| 3/14/2013 | Q4 2012 | ($0.27) | ($0.36) | | | View | N/A | |
| 11/14/2012 | Q312 | ($0.28) | ($0.24) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Fortress Biotech (NASDAQ:FBIO)2017 EPS Consensus Estimate: ($1.47)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.33) | ($0.33) | ($0.33) |
| Q2 2017 | 1 | ($0.37) | ($0.37) | ($0.37) |
| Q3 2017 | 1 | ($0.38) | ($0.38) | ($0.38) |
| Q4 2017 | 1 | ($0.39) | ($0.39) | ($0.39) |
(Data provided by Zacks Investment Research)
Dividend History for Fortress Biotech (NASDAQ:FBIO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Fortress Biotech (NASDAQ:FBIO)Insider Ownership Percentage: 31.54%
Institutional Ownership Percentage: 11.99%
Insider Trades by Quarter for Fortress Biotech (NASDAQ:FBIO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/16/2016 | George Avgerinos | SVP | Sell | 48,912 | $2.55 | $124,725.60 | |
| 12/1/2014 | Lucy Lu | CFO | Buy | 5,000 | $1.45 | $7,250.00 | |
| 11/6/2014 | Lindsay A Md Rosenwald | CEO | Buy | 150,000 | $1.61 | $241,500.00 | |
| 11/6/2014 | Malcolm Hoenlein | Director | Buy | 25,000 | $1.61 | $40,250.00 | |
| 11/6/2014 | Michael S Weiss | Major Shareholder | Buy | 1,000,000 | $1.61 | $1,610,000.00 | |
| 6/2/2014 | Lucy Lu | CFO | Buy | 5,000 | $1.37 | $6,850.00 | |
| 4/22/2014 | Kevin Horgan | Insider | Sell | 47,566 | $1.89 | $89,899.74 | |
| 4/21/2014 | Kevin Horgan | Insider | Sell | 19,000 | $1.81 | $34,390.00 | |
| 8/21/2013 | J Jay Lobell | Director | Buy | 5,000 | $7.37 | $36,850.00 | |
| 7/17/2013 | Lucy Lu | CFO | Buy | 4,545 | $7.90 | $35,905.50 | |
| 6/20/2013 | J Jay Lobell | Director | Buy | 10,000 | $7.62 | $76,200.00 | |
| 5/31/2013 | Dale Ritter | CAO | Buy | 1,503 | $3.88 | $5,831.64 | |
| 5/31/2013 | Lucy Lu | CFO | Buy | 4,979 | $3.88 | $19,318.52 | |
| 5/31/2013 | Noah D Beerman | COO | Buy | 5,000 | $3.88 | $19,400.00 | |
| 1/14/2013 | Harlan F Weisman | CEO | Buy | 20,000 | $5.71 | $114,200.00 | |
| 11/30/2012 | Glenn L Md Cooper | Insider | Buy | 3,811 | $4.02 | $15,320.22 | |
(Data available from 1/1/2013 forward)
Headline Trends for Fortress Biotech (NASDAQ:FBIO)
Latest Headlines for Fortress Biotech (NASDAQ:FBIO)
| Source: |
|
| Date | Headline |
|---|
 | Fortress Biotech (FBIO) versus MediWound (MDWD) Critical Comparison
www.americanbankingnews.com - September 17 at 4:26 AM |
 | Mustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed Immunotherapies
finance.yahoo.com - September 14 at 7:15 PM |
| Fortress Biotech, Inc. (FBIO) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - September 12 at 8:24 PM |
 | Mustang Bio to Present at the CAR-TCR Summit 2017 - GlobeNewswire (press release)
globenewswire.com - September 7 at 4:35 AM |
| Fortress Biotech to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
finance.yahoo.com - September 5 at 8:11 PM |
| Fortress Biotech, Inc. (FBIO) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 30 at 6:46 AM |
| ChemoCentryx (CCXI) and Fortress Biotech (FBIO) Critical Analysis
www.americanbankingnews.com - August 29 at 10:42 AM |
 | Mustang Bio Commences Trading on the NASDAQ Global Market - Nasdaq
www.nasdaq.com - August 24 at 4:58 AM |
 | Mustang Bio (MBIO) Commences Trading
www.streetinsider.com - August 23 at 11:56 PM |
| Mustang Bio Commences Trading on the NASDAQ Global Market - GlobeNewswire (press release)
globenewswire.com - August 23 at 12:08 AM |
| Mustang Bio Commences Trading on the NASDAQ Global Market
finance.yahoo.com - August 22 at 7:06 PM |
| Avenue Therapeutics Announces Appointment of Joseph Vazzano as Vice President of Finance and Corporate ... - GlobeNewswire (press release)
globenewswire.com - August 17 at 4:44 AM |
| Mustang Bio Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights - GlobeNewswire (press release)
globenewswire.com - August 14 at 6:55 PM |
| Fortress Biotech Forms New Subsidiary, Aevitas Therapeutics, Inc., to Develop Novel AAV Gene Therapy Treatments ... - GlobeNewswire (press release)
globenewswire.com - August 14 at 6:55 PM |
| Mustang Bio Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - August 14 at 6:55 PM |
| Fortress Biotech Forms New Subsidiary, Aevitas Therapeutics, Inc., to Develop Novel AAV Gene Therapy Treatments for Complement-Mediated Diseases
finance.yahoo.com - August 14 at 6:55 PM |
| Avenue Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - August 11 at 7:01 PM |
| Fortress Biotech Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - August 9 at 6:43 PM |
| Fortress Biotech reports 2Q loss
finance.yahoo.com - August 9 at 6:43 PM |
| Fortress Biotech, Inc. (FBIO) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - August 5 at 7:14 AM |
| Fortress Biotech, Inc. (FBIO) Expected to Post Quarterly Sales of $45.83 Million
www.americanbankingnews.com - July 29 at 7:21 AM |
| Checkpoint (CKPT): An Innovator of Immune-Enhanced Combination Therapies in Solid Tumors
finance.yahoo.com - July 28 at 4:45 PM |
| Fortress Biotech, Inc. (NASDAQ:FBIO) Expected to Post Earnings of -$0.34 Per Share
www.americanbankingnews.com - July 27 at 10:33 PM |
 | BRIEF-Fortress Biotech announces filing of provisional patent application for Caelum Biosciences' cael-101
www.reuters.com - July 18 at 12:28 AM |
| Fortress Biotech Announces Filing of Provisional Patent Application for Caelum Biosciences’ CAEL-101
finance.yahoo.com - July 17 at 11:54 AM |
| Fortress Biotech, Inc. (FBIO) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - July 12 at 12:04 AM |
| Fortress Biotech, Inc. (NASDAQ:FBIO) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 11 at 8:26 AM |
| Reviewing Catalyst Biosciences (CBIO) & Fortress Biotech (NASDAQ:FBIO)
www.americanbankingnews.com - July 4 at 6:26 PM |
| Fortress Biotech (FBIO) Shares March Higher, Can It Continue?
finance.yahoo.com - June 30 at 6:51 PM |
 | Avenue Therapeutics Completes Initial Public Offering
feeds.benzinga.com - June 30 at 11:40 AM |
| Pharmaceuticals Abound Among This Week's 11 IPOs
finance.yahoo.com - June 27 at 10:25 PM |
| Avenue Therapeutics IPO Info
www.streetinsider.com - June 27 at 5:23 PM |
| Avenue Therapeutics Prices Initial Public Offering of $33,000,000 of Common Stock
feeds.benzinga.com - June 26 at 8:36 PM |
| Checkpoint Therapeutics Commences Trading on the NASDAQ Capital Market
finance.yahoo.com - June 26 at 6:16 PM |
| Fortress Biotech to Present at the 2017 BIO International Convention
finance.yahoo.com - June 15 at 7:16 PM |
| Meet This Week's IPOs: A Biotech, A BDC And A Builder
finance.yahoo.com - June 13 at 11:36 AM |
| Fortress Biotech, Inc. (FBIO) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - June 13 at 10:04 AM |
| Fortress Biotech Inc (FBIO) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - June 7 at 3:32 PM |
| Fortress Biotech Announces that its Subsidiary, Mustang Bio, Enters into License Agreements with City of Hope for Novel CAR T Immunotherapies
finance.yahoo.com - June 5 at 11:19 AM |
| Fortress Biotech (FBIO) vs. Vitae Pharmaceuticals (VTAE) Head-To-Head Comparison
www.americanbankingnews.com - June 4 at 8:28 PM |
| Fortress Biotech (FBIO) Subsidiary Enters Biopharmaceutical Manufacturing Agreement With Patheon
www.streetinsider.com - June 1 at 5:52 PM |
| Fortress Biotech Subsidiary Caelum Biosciences Enters Biopharmaceutical Manufacturing Agreement With Patheon
finance.yahoo.com - June 1 at 5:52 PM |
| Checkpoint Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 1 at 5:52 PM |
 | A Profitable And Growing Microcap Investment Bank Focused On The Biotech Sector
seekingalpha.com - May 31 at 10:07 PM |
| Avenue Therapeutics Receives Notice of Allowance for a New Patent Application Covering Methods of Administration for Intravenous Tramadol
finance.yahoo.com - May 19 at 4:53 PM |
| Fortress Biotech (FBIO) Looks Good: Stock Adds 5% in Session
finance.yahoo.com - May 19 at 4:53 PM |
| Fortress Biotech Inc (FBIO) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - May 15 at 8:58 PM |
| ETFs with exposure to Fortress Biotech, Inc. : May 15, 2017
finance.yahoo.com - May 15 at 4:49 PM |
| Mustang Bio Reports First Quarter 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - May 15 at 4:48 PM |
| Q2 2017 EPS Estimates for Fortress Biotech Inc (FBIO) Boosted by FBR & Co
www.americanbankingnews.com - May 15 at 7:58 AM |
Fortress Biotech (FBIO) Chart for Thursday, September, 21, 2017
